President Trump’s strategy to lower prescription drug prices will be put to the test as drugmakers must now commit to the terms of his "Most Favored Nation" pricing plan or face unspecified actions from the federal government.

Trump gave drugmakers until Sept. 29 to respond to his Executive Order “Reducing Drug Prices for Americans and Taxpayers.”

The order calls on manufacturers to provide preferential pricing to all Medicaid patients, requires that they not give better prices to other developed countries on new drugs, create a way to sell directly to consumers and use trade policy to raise prices internationally so that revenue is reinvested into lowering American prices.

“Moving forward, the only thing I will accept from drug manufacturers is a commitment that provides American families immediate relief from the vastly inflated drug prices and an end to the free ride of American innovation by European and other developed nations,” Trump wrote to the drugmakers.

Should they refuse to engage, the order says the federal government will “deploy every tool in our arsenal to protect American families from continued abusive drug pricing practices.”

Trump sent letters to: AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Eli Lilly, EMD Serono, Genentech, Gilead, GSK, Johnson & Johnson, Merck, Novartis, Novo Nordisk, Pfizer, Regeneron and Sanofi.

How drug companies have responded so far

The Hill has reached out to all 17 companies named by the Trump........

© The Hill